Affiliations 

  • 1 Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
  • 2 Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah Province, Saudi Arabia
  • 3 Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Saudi Arabia
  • 4 Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University Dammam, Saudi Arabia
  • 5 Institute of Clinical Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom
Curr Diabetes Rev, 2021;17(4):503-511.
PMID: 32928091 DOI: 10.2174/1573399816666200914140939

Abstract

INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) are at significantly higher risk of developing cardiovascular diseases (CVD). There is a scarcity of literature reviews that describe and summarize T2DM patients' knowledge and perception about CVD prevention.

OBJECTIVES: To describe and summarize the assessment of knowledge and perceptions about CVD risk and preventive approaches among patients with T2DM.

METHODS: A scoping review methodology was adopted, and three scientific databases, Google Scholar, Science Direct, and PubMed were searched using predefined search terms. A multistage screening process that considered relevancy, publication year (2009-2019), English language, and article type (original research) was followed. We formulated research questions focused on the assessment of levels of knowledge and perceptions of the illness relevant to CVD prevention and the identification of associated patients' characteristics.

RESULTS: A total of 16 studies were included. Patients were not confident to identify CVD risk and other clinical consequences that may occur in the prognostic pathway of T2DM. Furthermore, patients were less likely to identify all CV risk factors indicating a lack of understanding of the multi-- factorial contribution of CVD risk. Patients' beliefs about medications were correlated with their level of adherence to medications for CVD prevention. Many knowledge gaps were identified, including the basic disease expectations at the time of diagnosis, identification of individuals' CVD risk factors, and management aspects. Knowledge and perceptions were affected by patients' demographic characteristics, e.g., educational level, race, age, and area of residence.

CONCLUSION: There are knowledge gaps concerning the understanding of CVD risk among patients with T2DM. The findings necessitate educational initiatives to boost CVD prevention among patients with T2DM. Furthermore, these should be individualized based on patients' characteristics, knowledge gaps, disease duration, and estimated CVD risk.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.